Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 5, 2011, Pages 372-375

  Dorschner, Julia ^a   Farmakis, Georgios ^a   Behnke, Stefanie ^a   Hellwig, Dirk ^a   Schneider, Susanne ^a   Fassbender, Klaus ^a   Kirsch, Carl Martin ^a   Dillmann, Ulrich ^a   Spiegel, Jörg ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Disease progression; MIBG scintigraphy; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; MALE; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RIGIDITY; TREMOR;

3-IODOBENZYLGUANIDINE; ADULT; AGED; FEMALE; HEART; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; MYOCARDIAL PERFUSION IMAGING; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79957962288     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.03.001     Document Type: Article

References (33)

1. Nakajo M., Shapiro B., Copp J., Kalff V., Gross M.D., Sisson J.C., et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983, 24:672-682.
2. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001, 11:351-355.
3. Orimo S., Ozawa E., Nakade S., Sugimoto T., Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67:189-194.
4. Sawada H., Oeda T., Yamamoto K., Kitagawa N., Mizuta E., Hosokawa R., et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson's disease. Eur J Neurol 2009, 16:174-182.
5. Spiegel J., Möllers M.O., Jost W.H., Fuss G., Samnick S., Dillmann U., et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005, 20:552-561.
6. Spiegel J., Hellwig D., Farmakis G., Jost W.H., Samnick S., Fassbender K., et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007, 22:1004-1008.
7. Okada Y., Ito Y., Aida J., Yasuhara M., Ohkawa S., Hirokawa K. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 2004, 54:682-687.
8. Orimo S., Takahashi A., Uchihara T., Mori F., Kakita A., Wakabayashi K., et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007, 17:24-30.
9. Orimo S. Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies. Rinsho Shinkeigaku 2008, 48:11-24.
10. Saiki S., Hirose G., Sakai K., Kataoka S., Hori A., Saiki M., et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of Parkinson's disease. J Neurol Sci 2004, 220:105-111.
11. Kim J.S., Lee K.S., Song I.U., Kim Y.I., Kim S.H., You I.R., et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci 2008, 270:122-126.
12. Suzuki M., Urashima M., Oka H., Hashimoto M., Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. Neuroreport 2007, 18:1867-1870.
13. Kim J.S., Shim Y.S., Song I.U., Yoo J.Y., Kim H.T., Kim Y.I., et al. Cardiac sympathetic denervation and its association with cognitive deficits in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:706-708.
14. Alves G., Wentzel-Larsen T., Aarsland D., Larsen J.P. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005, 65:1436-1441.
15. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., Muenter M.D. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989, 39:1187-1190.
16. Guillard A., Chastang C., Fenelon G. Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications. Rev Neurol (Paris) 1986, 142:207-214.
17. Hely M.A., Morris J.G., Traficante R., Reid W.G., O'Sullivan D.J., Williamson P.M. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999, 67:300-307.
18. Jankovic J., Kapadia A.S. Functional decline in Parkinson disease. Arch Neurol 2001, 58:1611-1615.
19. Guillard A., Chastang C. Long-term prognostic factors in Parkinson's disease. Rev Neurol (Paris) 1978, 134:341-354.
20. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
21. Louis E.D., Tang M.X., Cote L., Alfaro B., Mejia H., Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999, 56:334-337.
22. Yamada K., Shiraishi S.Y., Hamasaki T., Kuratsu J. Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease. Acta Neurochir (Wien) 2010, 152:2063-2068.
23. Fahn S., Elton R.L., Members of the UPDRS Development Committee Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-164. Macmillan Healthcare Information, Florham Park, HJ. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
24. Olanow C.W., Hauser R.A., Jankovic J., Langston W., Lang A., Poewe W., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-2201.
25. Hughes A., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
26. Piepsz A., Hahn K., Roca I., Ciofetta G., Toth G., Gordon I., et al. A radiopharmaceuticals schedule for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl Med 1990, 17:127-129.
27. Lassmann M., Biassoni L., Monsieurs M., Franzius C., Jacobs F., EANM Dosimetry and Paediatrics Committees The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2008, 35:1748.
28. Flotats A., Carrió I., Agostini D., Le Guludec D., Marcassa C., Schäfers M., et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010, 37:1802-1812.
29. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
30. Schrag A., Dodel R., Spottke A., Bornschein B., Siebert U., Quinn N.P. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007, 22:938-945.
31. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
32. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F-18 activity. Arch Neurol 2005, 62:378-382.
33. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.